索拉非尼
医学
瑞戈非尼
胰腺癌
癌症研究
基诺美
恶性肿瘤
癌症
药物开发
从长凳到床边
激酶
肿瘤科
药品
药理学
内科学
结直肠癌
肝细胞癌
生物
医学物理学
细胞生物学
作者
Paul Dent,Andrew Poklepovic,Laurence Booth,John F. Hancock
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2021-09-01
卷期号:32 (8): 779-785
被引量:2
标识
DOI:10.1097/cad.0000000000001177
摘要
Pancreatic cancer is an almost incurable malignancy whose incidence has increased over the past 30 years. Instead of pursuing the development of modalities utilizing 'traditional' cytotoxic chemotherapeutic agents, we have explored the possibilities of developing novel multi-kinase inhibitor drug combinations to kill this tumor type. Several approaches using the multi-kinase inhibitors sorafenib, regorafenib, and neratinib have been safely translated from the bench to the bedside, with objective anti-tumor responses. This review will discuss our prior preclinical and clinical studies and discuss future clinical opportunities in this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI